Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade

Table 2

Clinical data and ipilimumab treatment results of 70 patients with AJCC stage IV melanoma who received or did not receive melanoma vaccine.

Prior vaccination	Yes		No
		%		%
Patient number	35	50	35	50
M stage
M1A	8	23	3	9	0.3
M1B	8	23	10	28
M1C	19	54	22	63
Dose
3 mg/kg	30	86	32	91	0.45
10 mg/kg	5	14	3	9
Reinduction	4	12	3	9
Treatment stopped for toxicity	5	14	2	6
Objective response
CR	3	9	3	9	0.03
PR	10	29	4	11
S	6	17	1	3
P	16	46	27	77
Survival data
Median OS (months)	31 (3–47)		9 (2–50)		0.007
3-year survival rate	46%		19%

CR: complete response, PR: partial response, S: stable disease, and P: progression.
Pearson chi square (two-sided) test.
⁢ value for progression (P) versus any benefit (CR, PR, and S).